Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with Both SGLT2i and ARNI

Read full text Summarise with VIRAT
Authors: Stephen John Greene, Shachi Patel, Khaja Chinnakondepalli, Stefan D. Anker, Michael Böhm, Biykem Bozkurt, Javed Butler, John G.F. Cleland, Andrew J.S. Coats, Nihar Desai, Victoria Donachie, Ellie Kelepouris
+3 more Giuseppe M.C. Rosano, C. Brandes, Andrew J. Sauer
Cited by: 0
References: 5

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

For patients with heart failure (HF), randomized trials show that sodium glucose co-transporter-2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) (compared with angiotensin-converting enzyme inhibitor [ACEI]) therapies each decrease the risk of hyperkalemia (HK), including among those treated with mineralocorticoid receptor antagonists (MRA). 1 , 2 However, among patients with HF in routine clinical practice, the residual risk of HK despite use of SGLT2i and ARNI has not been characterized.

Fields of Study & Subjects

Potassium and Related Disorders Heart Failure Treatment and Management Diabetes Treatment and Management

Publication details

Journal / source
Journal of Cardiac Failure
Volume
32
Issue
10
Pages
1838–1841
Publication date
25 March 2026
Language
EN